Skip to main content
. 2020 Dec 11;35(1):75–87. doi: 10.1007/s40259-020-00456-5

Fig. 6.

Fig. 6

Biosimilar etanercept market shares for the seven health boards in Wales, calculated as volume (vials) of the biosimilars over volume of the biosimilars plus reference product, from quarter two of 2016 to end of 2018. The seventh health board, Powys Teaching Health Board, is not shown, as this health board has no secondary care services